DEC 1 6 2004

## Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 09/753,350 TRANSMITTAL Filing Date Art Unit 1644 (to be used for all correspondence after initial filing) **Examiner Name** P. Huynh 28+11 Attorney Docket Number Total Number of Pages in This Submission 252312005706

		refs			
ENCLOSURES (Check all that apply)					
	nittal Form + duplicate cessing (2 pages)	Drawing(s)		After Allowance Communication to TC	
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
X Amendment/Reply (19 pages)		Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After Final		Petition to Convert to a Provisional Application		Proprietary Information	
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address		Status Letter	
X Extension of Time Request (1 page)		Terminal Disclaimer		X Other Enclosure(s) (please Identify below):	
Express Abandonment Request		Request for Refund  CD, Number of CD(s)		Form PTO/SB/08a/b (1 page) Eleven (11) references Statement of Common Ownership (1 page)	
X Information Disclosure Statement, Supplemental (3 pages)				Return Receipt Postcard	
Certified Copy of Priority Document(s)		Landscape Table on CD			
Reply to Missing Parts/ Incomplete Application		Remarks			
Reply to Missing Parts under					
		i.			
	SIGNATI	JRE OF APPLICAN	IT, ATTORNEY, OR	AGENT	
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)				
Signature					
Printed name	John W. Tessman				
Date 12/16/04			Reg. No.	43,949	
			u ·		

	espondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 270751744 US, MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date
shown below.  Dated: 12/16/04	Signature:
	Toom Tessman)

Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number Effective on 12/08/2004. Complete if Known Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). Application Number 09/753.350 EE TRANSMITTAL Filing Date December 29, 2000 for FY 2005 First Named Inventor Stephen M. COUTTS Examiner Name P. Huynh Applicant claims small entity status. See 37 CFR 1.27 Art Unit 1644 690.00 TOTAL AMOUNT OF PAYMENT Attorney Docket No. 252312005706 METHOD OF PAYMENT (check all that apply) ☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): Deposit Account Deposit Account Number: 03-1952 Morrison & Foerster LLP Deposit Account Name: For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Credit any overpayments Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. FEE CALCULATION 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES **EXAMINATION FEES Application Type** FEE (\$) **Small Entity** Fee(\$) **Small Entity** Fee (\$) **Small Entity** Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) 500 200 0.00 Utility 300 150 250 100 65 0.00 200 100 50 130 Design 100 0.00 Plant 100 300 150 160 80 Reissue 300 150 500 250 600 300 0.00 0.00 100 Provisional 200 0 n O O 2. EXCESS CLAIM FEES **Small Entity** Fee Description Fee (\$) Fee(\$) Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent 50 25 Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent 200 100 Multiple dependent claims 360 180 **Multiple Dependent Claims Total Claims Extra Claims** Fee Paid (\$) <u>Fee (\$)</u> Fee Paid (\$) -31 25.00 Fee (\$) 31 180.00 0.00 HP + highest number of total claims paid for, if greater than 20 Indep. Claims Extra Claims Fee (\$) Fee Paid (\$) 100.00 0.00 HP + highest number of independent claims paid for, if greater than 3 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity)

## 4. OTHER FEE(S)

**Total Sheets** 

Non-English Specification, \$130 fee (no small entity discount)

/ 50 =

Information Disclosure Statement Fee

Extra Sheets

Other: Petition for Extension of Time, three months

ount) 180.00 <u>510.00</u>

Fee (\$)

Fee Paid (\$)

SUBMITTED BY

Signature Registration No. (Attorney/Agent) 43,949 Telephone (650) 813-5786

Name (Print/Type) John W. Tessman Date 12/16/04

Number of each additional 50 or fraction thereof

(round up to a whole number) x

for each additional 50 sheets or reaction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 270751744 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 2004

Signature:

Georgina Matos)



252312005706 (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Stephen M. COUTTS et al.

Application No.: 09/753,350

Filed: December 29, 2000

For: CONJUGATES OF T CELL EPITOPE

DEFICIENT IMMUNOGEN ANALOGS FOR HUMORAL ANERGY AND CHEMICALLY DEFINED NON-POLYMERIC VALENCY

PLATFORM MOLECULES

Confirmation No.: 1391

Art Unit: 1644

Examiner: P. Huynh

## STATEMENT OF COMMON OWNERSHIP

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The below signed hereby certifies that U.S. patent number 6,060,065 and the invention for which claims are currently pending in the above referenced application were owned by, or subject to an obligation of assignment to, La Jolla Pharmaceutical Company at the time the abovereferenced invention was made.

Dated: -

Respectfully submitted,

Andrew Wiseman

Sr. Director of Business Development La Jolla Pharmaccutical Company